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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract Postoperative vomiting (POV) is a common complication after general anesthesia.
Clarifying the genetic factors that affect POV are important for evaluating a patient’s suscep-
tibility to the condition. Although evidence suggests that the 5-hydroxytryptamine (serotonin)
receptor 3A (HTR3A) gene may be important in the occurrence of POV, associations for HTR3A
polymorphisms with POV have not been investigated in a Taiwanese population. Three single
nucleotide polymorphisms (SNPs) of the HTR3A gene were used to study the genetic association
with POV in 369 postoperative Taiwanese adults who underwent general anesthesia. Although
no significant differences were found at the single-locus level for HTR3A polymorphisms, a sig-
nificant haplotype-based association was found between HTR3A and POV. In addition, because
female sex is associated with a higher risk of PONV (postoperative nausea and vomiting), we
separately analyzed the haplotypic associations for both sexes to test whether HTR3A genetic
factors interact with female sex and specifically contribute to the etiology of POV. We found
that a significant haplotype effect was identified only for females. The CTT haplotype, the
most common, showed a significant protective effect (odds ratio: 0.68), and the CTG haplo-
type was associated with a significantly higher risk (odds ratio: 2.08) for POV in females.
Furthermore, p values from an overall comparison of all haplotypes and from permutation testsBiomedical Sciences, National Chung Hsing University, 250 Kuo-Kuang Road, Taichung 40227, Taiwan.
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60 Y.-M.J. Lin et al.were still significant. These data suggest that the HTR3A gene may have a sex-specific effect
on the etiology of POV in Taiwan. The effects and the biological causal variants related to POV
are worth additional investigation.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Postoperative vomiting (POV) is a common but important
complication after anesthesia. POV is accompanied by
postoperative nausea (PON) and summarized as PONV
(postoperative nausea and vomiting). Without prophylactic
medication, PONV in the postoperative period is approxi-
mately 20e30%, but may even rise to 80% in high-risk
patients.1e3 A family history has been proposed as an
important risk factor for PONV, and genetic factors have
been suggested as important modulators of the occurrence
and phenotypic variability of PONV.4,5 Thus, identifying
specific genetic variations associated with increased sus-
ceptibility or just identifying specific subtypes of PONV
should contribute a great deal to its prevention. Physiolog-
ically, PON and POVare two related but distinct phenomena.
They have different incidences: PON usually has a higher
incidence than POV.6,7 Because we hypothesized that the
risk factors involved were different8,9 and that they should
be separately analyzed, the present study specifically
focused on identifying the genetic component of POV.
Serotonin type 3 (5-hydroxytryptamine type 3; 5-HT3)
receptors are pentameric ligand-gated ion channels of the
Cys-loop receptor superfamily. The activation of 5-HT3 re-
ceptors mediates fast excitatory responses of neurotrans-
mission in the central nervous system (CNS) and peripheral
nervous system (PNS).10 5-HT3 receptors are expressed in
different regions and modulate many diverse physiological
functions, including the initiation of the vomiting
reflex.11e13 The function of 5-HT3 receptors in diseases and
drug development has been intensively studied. For
example: 5-HT3 receptors are involved in the mediation of
several different diseases such as schizophrenia, irritable
bowel syndrome, nausea, and vomiting.14e16 This may help
to give direction to personalized medicine that could tailor
therapies to more individual healthcare.17
Current research suggests that 5-HT3 receptors are
important in the etiology of POV. A theory related to the
vomiting mechanism has proposed that the activation of 5-
HT3 receptors in the chemoreceptor trigger zone (CTZ) of the
brain can provoke emesis, or on gastrointestinal vagal affer-
ents, which send signals directly to the vomiting center in the
medulla oblongata.12,13 Moreover, recent research17 says that
antagonists which target 5-HT3 receptors can be used to
prevent and suppress POVby inhibiting serotonin frombinding
to 5-HT3 receptors. Therefore, we hypothesized that genetic
variations in HTR3 genes modulate susceptibility to POV.
Among the five different subunit genes of HTR3 (HTR3AeE),
HTR3A is essential in the functional HTR3 channel. HTR3A is
also the only single component that can form functional
homopentameric channels, and all other subunit subtypes
must heteromerize with HTR3A subunits.18,19Although the HTR3A gene has attracted interest for its
effects on POV because of its important role in the physi-
ology of vomiting and clinical successes using HTR3 antag-
onists,20e23 there has been no thorough assessment of POV
in Taiwanese patients who carry the HTR3A polymorphisms.
In this study, we evaluate the risk of HTR3A polymorphisms
of POV after general anesthesia in a Taiwanese population.
In addition, a growing body of research has reported that
female patients are particularly susceptible to PONV after
general anesthesia.24e26 Our study also separately assesses
for males and females the genetic risk of HTR3A gene
polymorphisms on POV.Materials and methods
Study participants and DNA preparation
Adult patients (>20 years old) scheduled to undergo gen-
eral anesthesia were recruited to join the prospective
perioperative outcome cohort. The Ethics Committee of
the Ditmanson Medical Foundation Chia-Yi Christian Hospi-
tal granted approval for this study. Signed and written
informed consent was obtained from all participants. Pa-
tients with nine different types of surgeries were recruited:
lower abdominal (Operation 1; Op.1), upper abdominal
(Op.2), thoracic (Op.3), cardiac (Op.4), spinal (Op.5),
laparoscopic intra-abdominal (Op.6), thyroid (Op.7), breast
(Op.8), and oral (Op.9).
Patient demographic datadsex, age, body weight,
height, calculated BMI, smoking status, alcohol drinking
status, and other validated PONV risksdwere collected
during preoperative visits to the ward. Regular monitoring
[noninvasive arterial pressure measurement, electrocardi-
ography with heart rate, and arterial oxygen saturation
(pulse oximetry)] began before the induction of anesthesia.
After preoxygenation, anesthesia was administered using
standard tracheal intubation. All patients underwent
volume-controlled ventilation with a tidal volume of
7e10 mL/kg and a respiratory rate of 10e12 breaths/min-
ute without nitrous oxide. The anesthetic used and details
about the patient’s course were intraoperatively docu-
mented. Recording of specific anesthetic drugs focused on
which volatile was used, and the types and doses of opioids
that were used irrespective of the specific compound.
Three hundred sixty-nine patients who had undergone
general anesthesia and who met inclusion criteria were
considered for the current study. Patients undergoing
emergency surgery, those who could not communicate
well, and those who refused to participate in our study
were excluded. To remove the possible influence on PONV
outcomes, patients who took prophylactic drugs, such as
Table 1 Demographic data of individuals collected in this
study.
POV Non-POV p*
Sex (F/M) 93/15 147/149 <0.001
Smoking status (N/Y) 91/17 172/124 <0.001
Alcohol drinking (N/Y) 100/6 226/70 <0.001
History of PONV (N/Y) 100/8 288/8 0.037
Operation types 0.022
Lower abdominal 26 93
Upper abdominal 6 56
Thoracic 15 32
Cardiac 2 4
Spinal 4 7
Laparoscopic intra-abdominal 11 21
Thyroid 30 61
Breast 11 19
Oral 3 3
F Z female; M Z male; N Z no; PONV Z postoperative vom-
iting and nausea; POV Z postoperative vomiting; Y Z yes.
*Chi-square tests were used to perform statistical analysis of
differences between the groups.
Postoperative vomiting and HTR3A gene 61steroids or droperidol, patients who did not take any
postoperative opioids and patients who took antiemetics
were excluded. Genomic DNA was prepared from peripheral
blood using DNA extraction kits (QuickGene DNA Whole
Blood Kit; Fujifilm Life Science, Stamford, CT, USA).
POV scoring method
The main outcome of interest was any incidence of POV
during a 24-hour postoperative observation period. A
research assistant interviewed the patients in the post-
anesthesia recovery (PAR) room and 24 hours after they had
returned to the ward about their instances of POV. All
recorded answers were dichotomized into “yes” or “no”,
and were labeled as the POV incidence in 24 hours. The
severity of the vomiting was not considered.
Marker selection and genotyping procedures
Selected SNPs of the HTR3A gene were genotyped and
analyzed for a genetic association with the POV phenotype.
To test whether the HTR3A genotype has different effects
on the incidence of POV, the participants were assigned to
the POV group (POV at least once within the first 24 post-
operative hours) or controls (no POV within the first 24
postoperative hours). Three SNPs within the human HTR3A
gene regiondrs33940208, rs1985242, and
rs10160548dwere selected from the dbSNP database
(http://www.ncbi.nlm.nih.gov/SNP), depending on their
genomic distribution, allele frequencies in our population
and their relative functional significance. SNPs with minor
allele frequency (MAF) < 0.05 were excluded.27 A high-
throughput assay (predesigned TaqMan SNP Assays;
Applied Biosystems, Foster City, CA, USA) was used to ge-
notype all participants with a sequence detecting system
(ABI PRISM 7500; Applied Biosystems).
Statistical analysis
A c2 test (SNPAlyze 4.1; Dynacom, Kanagawa, Japan) was
used to analyze both the Hardy-Weinberg equilibrium of
each marker and the differences in genotypic and allelic
distributions between patients with POV and controls.
Standardized pairwise disequilibrium coefficients (D0) for
measuring linkage disequilibrium between the three SNPs,
the construction of haplotypes, and haplotype-based asso-
ciation were also estimated using SNPAlyze. The Graphical
Overview of Linkage Disequilibrium (GOLD) program
(http://www.sph.umich.edu/csg/abecasis/GOLD/) was
used to plot the linkage disequilibrium distribution.28
Results
From 2009 to 2011, 1500 eligible patients were invited to
participate in this study. They were all adults scheduled to
undergo general anesthesia for different types of surgery.
In all, 960 surgical patients with completed case report
forms of PONV were recruited. In addition to 223 patients
transferred directly to the Intensive Care Unit (ICU), there
were 737 with PONV data from the PAR. Patients who didnot meet our inclusion criteria were excluded. Patients
undergoing bariatric surgery, 100% of whom had PONV,
were also excluded from the final dataset. Finally, 369
patients participated in this study. The collected de-
mographic data and some reported risk factors of PON were
used to evaluate the risk effect on POV occurrence and are
shown in Table 1. These reported PONV risk factors also
showed a significant association with POV occurrence dur-
ing 24 postoperative hours in our examined population.
Polymorphism genotyping and single-locus
association analysis
Three selected SNPs from all our participants were geno-
typed. The genotyping coverage was about 94%; the missing
rates ranged from 0% to 14%. The genotype distributions of
all studied SNPs in both groups were in HWE
(p Z 0.12e0.99). General population-based allele fre-
quencies were similar to the data from the dbSNP.
The associations of each polymorphism of the HTR3A
gene and patients with POV were analyzed to compare
allelic and genotypic frequencies between the two groups
using the Pearson c2 test. There were no significant differ-
ences in single alleles or genotype distributions (Table 2).
Linkage disequilibrium mapping and risk haplotype
analysis
Pairwise linkage disequilibrium (LD) analyses were done
between the three SNPs across the HTR3A gene in all pa-
tients. Pairwise LD coefficients (D0 values) were estimated
to represent the LD (Fig. 1). The LD patterns are distinctly
different between the two study populations. In patients
without POV, strong LD was detected between adjacent
SNP pairs (D0 from 0.70 to 0.98), and the D0 slightly dropped
as the distance between the pairs increased (D0 Z 0.56
between rs33940208 and rs10160548). In contrast, strong LD
Table 2 Genotypic and allelic distribution of human HTR3A gene polymorphisms.
SNP (alternative
alleles)
Group (N) Genotypea
Number (frequency)
Pearson c2
test p
Allelea
Number (frequency)
Pearson c2
test p
11 12 22 1 2
rs33940208 (C/T) Vomiting (98) 63 (0.64) 29 (0.30) 6 (0.06) 0.79 155 (0.79) 41 (0.21) 0.57
Female/male 54/9 24/5 6/0
Nonvomiting (271) 164 (0.61) 90 (0.33) 17 (0.06) 418 (0.77) 124 (0.23)
Female/male 82/82 46/44 6/11
rs1985242 (T/A) Vomiting (96) 36 (0.38) 45 (0.47) 15 (0.16) 0.80 117 (0.61) 75 (0.39) 0.93
Female/male 30/6 37/8 15/0
Nonvomiting (261) 104 (0.40) 112 (0.43) 45 (0.17) 320 (0.61) 202 (0.39)
Female/male 53/51 62/50 17/28
rs10160548 (T/G) Vomiting (84) 31 (0.37) 39 (0.46) 14 (0.17) 0.93 101 (0.60) 67 (0.40) 0.78
Female/male 25/6 34/5 13/1
Nonvomiting (234) 88 (0.38) 111 (0.47) 35 (0.15) 287 (0.61) 181 (0.39)
Female/male 49/39 51/60 16/19
SNP Z single nucleotide polymorphism.
a Major allele Z 1, minor allele Z 2.
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between rs33940208 and rs1985242 (D0 Z 1), and dropped
faster for long-distance SNP-pairs (D0 from 0.03 to 0.52).
The distinct LD patterns suggested a possible disease-
related effect; therefore, we investigated the genetic as-
sociations in haplotype-based analysis.
In our current analysis, there were five common haplo-
types with a frequency >5% in all participants. Haplotype-
based genetic association tests were done using the esti-
mated haplotype frequencies. Although there was no single
locus association between any HTR3A polymorphisms in pa-
tients with POV, there was a significantly different distri-
bution of several haplotypes between groups (Table 3). In
addition, significant differences were detected even after a
rigid 1000 consecutive permutation tests. Haplotype TAGFigure 1 Linkage disequilibrium (LD) plot in the HTR3A gene. Ab
calculated to represent pairwise linkage disequilibrium of the HTR3
POV. LD was plotted using the Graphical Overview of Linkage Dis
(D0 Z 1), and blue indicates no linkage (D0 Z 0). The three polycarries a significant protective effect (permutation
p Z 0.018; OR: 0.56; 95% CI: 0.34e0.93). Both haplotypes
CTG and TAT were associated with significantly risk effects
(permutation p Z 0.043 and 0.032; OR: 1.72 and 1.78; 95%
CI: 1.02e2.90 and 1.03e3.03, respectively). Significant dif-
ferences were also assessed in overall haplotype frequency
profiles (total pZ 0.008; global permutation pZ 0.005).Sex-specific risk haplotype analysis
The female sex risk for POV was also evaluated. Significant
associations between female sex and POV occurrence dur-
ing 24 postoperative hours were found in our population
(Table 1; p for Pearson c2: <0.001). To investigate sex-solute standardized linkage disequilibrium coefficient (D0) was
A single nucleotide polymorphisms in patients with and without
equilibrium (GOLD) program. Red indicates complete linkage
morphisms are listed in the 50/30- orientation (left to right).
Table 3 Haplotype frequency and test statistics between patients with and without POV.
Haplotypea Number (frequency) p OR (95% CI) Permutation testb
Overall Non-POV POV
CTT 424 (0.53) 319 (0.54) 105 (0.49) 0.193 0.81 (0.59e1.11) 0.197
CAG 132 (0.17) 93 (0.16) 39 (0.18) 0.416 1.19 (0.79e1.79) 0.447
TAG 116 (0.14) 95 (0.16) 21 (0.10) 0.024 0.56 (0.34e0.93) 0.018
CTG 67 (0.08) 42 (0.07) 25 (0.12) 0.040 1.72 (1.02e2.90) 0.043
TAT 63 (0.08) 39 (0.07) 24 (0.11) 0.033 1.78 (1.04e3.03) 0.032
Total p value 0.008
Global p value of permutation testc 0.005
POV Z postoperative vomiting.
a Haplotypes were constructed with HTR3A SNPs: (from left to right) rs33940208, rs1985242, and rs10160548.
b One thousand permutations were replicated to evaluate the permutation p value.
c The global p value was calculated using a permutation test (n Z 1000).
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HTR3A haplotypes and the occurrence of POV occurrence,
males and females were separately analyzed for haplotype-
based genetic associations. Neither single nor overall
haplotype carriers were significantly associated with POV
for males, but they were for females (Table 4). The overall
comparison of all haplotypes were significantly different
between female patients with and without POV (total
p Z 0.006; global permutation p Z 0.009). In single
haplotype analysis, CTG and TAT haplotypes were also
significantly different between patients with and without
POV (p Z 0.025 and 0.04, respectively), and showing risk
effects (OR: 2.08 and 1.98, respectively), but the signifi-
cance for the distribution of the TAT haplotype disappeared
in a permutation test (p Z 0.055). In addition, the most
common haplotype, CTT, which has a female-specific pro-
tective effect, (permutation p Z 0.048; OR: 0.68; 95% CI:
0.47e0.99) was not detected when both males and females
were analyzed together. These data imply the involvement
of the HTR3A gene in the development of POV in female
surgical patients.Discussion
POV is one of the major postoperative concerns for pa-
tients. One recent study29 suggests that using associationTable 4 Haplotype frequency and test statistics between fema
Haplotypea Number (frequency
Overall Non-POV
CTT 254 (0.53) 167 (0.57)
CAG 81 (0.17) 45 (0.15)
TAG 64 (0.13) 46 (0.16)
CTG 40 (0.08) 18 (0.06)
TAT 39 (0.08) 18 (0.06)
Total p value 0.006
Global p value of permutation testc 0.009
POV Z postoperative vomiting.
a Haplotypes were constructed with HTR3A SNPs: (from left to right
b One thousand permutations were replicated to evaluate the perm
c The global p value was calculated using a permutation test (n Zanalysis will provide acceptable power to detect genetic
effects on complex phenotypic traits like POV. The pre-
sent study investigated the effect of the HTR3A gene ef-
fect on POV susceptibility in the Taiwanese population.
Although female sex is one of the well-recognized risk
factors for PONV,1,24e26 rational explanations for the
biological mechanism have not been presented. The
increased incidence in female patients persists
throughout life, even following menopause, which ex-
cludes the modulating effect of reproductive hormones.30
Confounding factors will affect a diversified incidence. To
minimize effects from this important confounder, we
separately tested the genetic contribution of the HTR3A
gene in both sexes.
In the present study, we found that, although the
selected HTR3A gene polymorphisms were not significantly
associated with POV on single-locus level, LD-mapping and
the interaction-considered haplotype-based analysis
showed that the HTR3A gene had a significant effect on
POV. In agreement with the widely accepted theory that
haplotype-based combinations of multiple loci has a dra-
matic impact on the etiology of diseases, when associations
with disease at single locus level are not significant.31,32
Most importantly, when we separately analyzed the
haplotype associations, the significant haplotype was
detected only in groups of females but not in groups of
males.le patients with and without POV.
) p Odds ratio (95% CI) Permutation testb
POV
87 (0.47) 0.042 0.68 (0.47e0.99) 0.048
36 (0.20) 0.227 1.35 (0.83e2.18) 0.251
18 (0.10) 0.067 0.58 (0.33e1.04) 0.070
22 (0.12) 0.025 2.08 (1.08e3.99) 0.034
21 (0.11) 0.040 1.98 (1.02e3.82) 0.055
) rs33940208, rs1985242, and rs10160548.
utation p value.
1000).
64 Y.-M.J. Lin et al.There are several risk factors for PONV: sex,
nonsmoking, history of motion sickness or PONV, post-
operative opioid use, and so on.33 Nonetheless, previous
epidemiologic investigations indicate that there is no reli-
able independent predictor.30 For example, although a
history of PONV suggests a high risk of susceptibility, the
prediction rate was poor using the patient’s history alone,
whereas the four-factor risk score was significantly bet-
ter.34 The present study provides additional evidence that
female sex and in particular HTR3A haplotypes interact and
this information should allow a more stratified and precise
prediction of the occurrence of POV. Many scoring systems
have been developed to identify clinical risk parameters
and to establish PONV prediction models,34e36 but most of
them have only moderate discriminating power and,
therefore, are not clinically accurate or useful. Apparently,
some important risk factors were missed, including possible
genetic factors. Our current finding suggests the sex-
specific genetic risk of the HTR3A haplotype can be
included to improve the discriminating power of current
PONV prediction system.
Haplotype-based analysis allows multiple potentially
causal loci to be simultaneously tested for genetic asso-
ciations, and might represent the interactive effect of
assayed markers and the potential effect of untyped
causal markers.37 Results from our haplotype analyses
imply a possibility of interactions between different SNPs
of the HTR3A gene. In haplotype analyses of female pa-
tients, the CTT haplotype showed a significant protective
effect (OR Z 0.68; 95% CI Z 0.47e0.99). In contrast, the
CTG haplotype (which replaces a “T” allele of rs10160548
with a “G” allele) showed a significant risk for POV
(OR Z 2.08; 95% CIZ 1.08e3.99). The results for the TAG
and TAT haplotypes were similar: the alternative third-
position allele was also associated with inverse distribu-
tions in the two groups, although the significant differ-
ences observed only when both males and females were
analyzed together. These data suggest a possible inter-
action between two 50 polymorphisms with the third allele
of rs10160548 determines the significant effect. Although
there was no detectable effect based on rs10160548
alone, our results indicated that the rs10160548 poly-
morphism may have a potential to modify the gene effects
in the form of haplotypes. The possible interaction was
also supported by our LD-mapping data: there is distinct
LD of rs10160548 with other polymorphisms between the
two study groups. Although it has not yet been confirmed,
the interaction between the sites of polymorphisms that
modify the effects of genes on disease development has
been previously reported31: interaction between sites of
the b2-adrenoceptor gene is associated with a protective
effect against asthma.
Most current research on the effects of genetic poly-
morphisms on nausea and vomiting are focused on their
pharmacogenetic roles: they investigate the efficacy of
nausea- and vomiting-related drugs23,38e42; specific-drug-
induced nausea and vomiting (i.e., chemotherapy, antide-
pressant); and so on. For example, the polymorphism of the
m-opioid receptor gene OPRM1:c.118A > G was recently
reported42 not to protect against intravenous patient
controlled analgesia morphine-induced nausea or vomiting.
Polymorphisms of the HTR3B, COMT, and CHRM3 genes maybe correlated with the variability of nausea in cancer pa-
tients taking opioids.38 The roles of the HTR3A and HTR3B
genes as pharmacogenetic predictors for antiemetic treat-
ment in patients with cancer have also been tested.40,41
There are still few genetic risk factors used to predict
POV or PONV. One study on a Japanese population43 showed
that dopamine type-2 receptor (DRD2) Taq1A polymorphism
is associated with the occurrence of early PONV, and one
SNP within the CHRM3 gene was significantly associated
with PONV in a genome-wide association study.44
The present study differed from above studies because it
specifically focused on investigating the genetic de-
terminants of POV only. Clearly phenotypic dissection have
been promised as a key point to successfully mapping the
genetic components of diseases with complex etiology.45
Our results support the phenotypic dissection strategy
which assumes that only one specific clinical symptom can
successfully identify and provide new insight into the ge-
netic components of PONV, which is a heterogeneous event.
There is another study applied the phenotypic dissection
strategy to study the genetic components of POV only, and
successfully identified the POV associated genes.46
Although the observation periods (6 hours after surgery in
Rueffer’s study) and studied polymorphisms are different,
both data from our and Rueffer’s study suggest that the
genetic variations of the HTR3A gene is associated with
developing POV.
Our findings suggest that the HTR3A haplotypes are
significantly associated with the POV of Taiwanese female
patients during the first 24 postoperative hours. That two
of the three polymorphisms that we assessed in this study
are located on introns, and that fact the significant as-
sociation can be detected only using haplotype-based
analysis and does not appear in single-locus analysis im-
plies that the biological functional variants related to
POV could be other variants within the HTR3A gene or
neighboring genes, and that they are worth additional
investigation. In particular, the gene that encodes
HTR3B, is located just beside the HTR3A gene, and spe-
cifically modifies its function is a good candidate for
further investigation.19,47 However, the functional ef-
fects of these three polymorphisms should not, there-
fore, be neglected. They may have minor regulatory
effects that could not be determined in the present
study. Although the finding from our genetic analysis
seems significant, because of the limited sample size, the
chances of false-positives cannot be totally excluded.
Thus, further investigations with larger Taiwanese co-
horts are required to confirm the significance of the
HTR3A gene on the etiology of POV in Taiwan. To our
knowledge, the present study is the first to show that the
HTR3A gene haplotype may affect the incidence of POV in
Taiwanese female under general anesthesia. Results from
this study are worth validating in an independent cohort,
and have the potential to become population-specific
predictive biomarkers for sex-specific POV in the Taiwa-
nese population.Conflicts of interest
All authors have no conflicts of interest to declare.
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